A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan, FT; Hillmen, P; Hellmann, A; Robak, T; Hughes, SG; Trone, D; Shannon, M; Flinn, IW; Byrd, JC; Br J Haematol. 2014; 167(4): 466-477.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts, C; Socinski, MA; Mitchell, PL; Thatcher, N; Havel, L; Krzakowski, M; Nawrocki, S; Ciuleanu, TE; Bosquée, L; Trigo, JM; Spira, A; Tremblay, L; Nyman, J; Ramlau, R; Wickart-Johansson, G; Ellis, P; Gladkov, O; Pereira, JR; Eberhardt, WE; Helwig, C; Schröder, A; Shepherd, FA; Lancet Oncol. 2014; 15(1): 59-68.

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

Guglielmelli, P; Biamonte, F; Rotunno, G; Artusi, V; Artuso, L; Bernardis, I; Tenedini, E; Pieri, L; Paoli, C; Mannarelli, C; Fjerza, R; Rumi, E; Stalbovskaya, V; Squires, M; Cazzola, M; Manfredini, R; Harrison, C; Tagliafico, E; Vannucchi, AM; Blood. 2014; 123(14): 2157-2160.

Kasabach-Merritt phenomenon in hepatic angiosarcoma.

Habringer, S; Boekstegers, A; Weiss, L; Hopfinger, G; Meissnitzer, T; Melchardt, T; Egle, A; Greil, R; Br J Haematol. 2014; 167(5):716-718

αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Berghoff, AS; Kovanda, AK; Melchardt, T; Bartsch, R; Hainfellner, JA; Sipos, B; Schittenhelm, J; Zielinski, CC; Widhalm, G; Dieckmann, K; Weller, M; Goodman, SL; Birner, P; Preusser, M; Clin Exp Metastasis. 2014; 31(7):841-851

Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study.

Leierer, G; Rieger, A; Steuer, A; Sarcletti, M; Geit, M; Haas, B; Taylor, N; Kanatschnig, M; Rappold, M; Ledergerber, B; Zangerle, R; J Int AIDS Soc. 2014; 17(4 Suppl 3):19667

Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014.

Rappold, M; Rieger, A; Steuer, A; Geit, M; Sarcletti, M; Haas, B; Taylor, N; Kanatschnig, M; Leierer, G; Ledergerber, B; Zangerle, R; J Int AIDS Soc. 2014; 17(4 Suppl 3):19768

Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia.

Rebhandl, S; Huemer, M; Zaborsky, N; Gassner, FJ; Catakovic, K; Felder, TK; Greil, R; Geisberger, R; Eur J Immunol. 2014; 44(7):2175-2187

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Benner, A; Mansouri, L; Rossi, D; Majid, A; Willander, K; Parker, A; Bond, G; Pavlova, S; Nückel, H; Merkel, O; Ghia, P; Montserrat, E; Kaderi, MA; Rosenquist, R; Gaidano, G; Dyer, MJ; Söderkvist, P; Linderholm, M; Oscier, D; Tvaruzkova, Z; Pospisilova, S; Dührsen, U; Greil, R; Döhner, H; Stilgenbauer, S; Zenz, T; Haematologica. 2014; 99(8): 1285-1291.

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Huemer, F; Gampenrieder, SP; Schlattau, A; Greil, R; Clin Breast Cancer. 2014; 14(1):e17-e20